NASDAQ:KLDOKaleido Biosciences Stock Price, Forecast & News

Kaleido Biosciences' stock was trading at $5.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KLDO shares have increased by 19.3% and is now trading at $6.61. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kaleido Biosciences.

Kaleido Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Kaleido Biosciences.

Kaleido Biosciences Inc (NASDAQ:KLDO) issued its earnings results on Thursday, May, 14th. The company reported ($0.64) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.64). View Kaleido Biosciences' earnings history.

2 analysts have issued 1-year target prices for Kaleido Biosciences' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Kaleido Biosciences' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price. View analysts' price targets for Kaleido Biosciences.

News coverage about KLDO stock has trended somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kaleido Biosciences earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutKaleido Biosciences.

Kaleido Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,380,000 shares, an increase of 7.7% from the April 30th total of 2,210,000 shares. Based on an average daily trading volume, of 121,800 shares, the short-interest ratio is currently 19.5 days. Approximately 24.4% of the company's stock are sold short. View Kaleido Biosciences' Current Options Chain.

Some companies that are related to Kaleido Biosciences include Collegium Pharmaceutical (COLL), BAVARIAN NORDIC/S (BVNRY), Opthea (OPT), Cara Therapeutics (CARA), Replimune Group (REPL), Heska (HSKA), Kura Oncology (KURA), BellRing Brands (BRBR), AdaptHealth (AHCO), Adaptimmune Therapeutics (ADAP), Kadmon (KDMN), Molecular Templates (MTEM), ZIOPHARM Oncology (ZIOP), Aerie Pharmaceuticals (AERI) and Sienna Senior Living (SIA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Tcr2 Therapeutics (TCRR), Harpoon Therapeutics (HARP), QUALCOMM (QCOM) and Exxon Mobil (XOM).

(KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Kaleido Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.84%), State Street Corp (0.48%), Geode Capital Management LLC (0.43%), Victory Capital Management Inc. (0.41%), Victory Capital Management Inc. (0.41%) and Invesco Ltd. (0.27%). Company insiders that own Kaleido Biosciences stock include Michael W Bonney and Ventures Fund V LP Flagship. View institutional ownership trends for Kaleido Biosciences.

KLDO stock was sold by a variety of institutional investors in the last quarter, including Bainco International Investors, Morgan Stanley, UBS Group AG, Victory Capital Management Inc., Victory Capital Management Inc., and First Trust Advisors LP. View insider buying and selling activity for Kaleido Biosciences.

KLDO stock was bought by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Nuveen Asset Management LLC, State Street Corp, Geode Capital Management LLC, Parametric Portfolio Associates LLC, Bank of New York Mellon Corp, and Citigroup Inc.. Company insiders that have bought Kaleido Biosciences stock in the last two years include Michael W Bonney, and Ventures Fund V LP Flagship. View insider buying and selling activity for Kaleido Biosciences.

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KLDO stock can currently be purchased for approximately $6.61.

Kaleido Biosciences has a market capitalization of $201.54 million. Kaleido Biosciences employs 118 workers across the globe.